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Stable preparations of tyrosine 
hydroxylase provide the solution 
structure of the full-length enzyme
Maria T. Bezem1,*, Anne Baumann1,2,3,*, Lars Skjærven1, Romain Meyer4, Petri Kursula1, 
Aurora Martinez1,2 & Marte I. Flydal1,5
Tyrosine hydroxylase (TH) catalyzes the rate-limiting step in the biosynthesis of catecholamine 
neurotransmitters. TH is a highly complex enzyme at mechanistic, structural, and regulatory levels, 
and the preparation of kinetically and conformationally stable enzyme for structural characterization 
has been challenging. Here, we report on improved protocols for purification of recombinant human TH 
isoform 1 (TH1), which provide large amounts of pure, stable, active TH1 with an intact N-terminus. TH1 
purified through fusion with a His-tagged maltose-binding protein on amylose resin was representative 
of the iron-bound functional enzyme, showing high activity and stabilization by the natural feedback 
inhibitor dopamine. TH1 purified through fusion with a His-tagged ZZ domain on TALON is remarkably 
stable, as it was partially inhibited by resin-derived cobalt. This more stable enzyme preparation 
provided high-quality small-angle X-ray scattering (SAXS) data and reliable structural models of full-
length tetrameric TH1. The SAXS-derived model reveals an elongated conformation (Dmax = 20 nm) for 
TH1, different arrangement of the catalytic domains compared with the crystal structure of truncated 
forms, and an N-terminal region with an unstructured tail that hosts the phosphorylation sites and a 
separated Ala-rich helical motif that may have a role in regulation of TH by interacting with binding 
partners.
Tyrosine hydroxylase (TH, 1.14.16.2)  cata lyzes  the conversion of  L-tyrosine (L-Tyr)  to 
L-3,4-dihydroxyphenylalanine (L-DOPA), which is the rate-limiting step in the synthesis of the catecho-
lamine neurotransmitters and hormones dopamine (DA), noradrenaline, and adrenaline1. TH requires an 
enzyme-bound non-heme ferrous iron (Fe2+), 6R-tetrahydrobiopterin (BH4) as cofactor, and molecular oxygen 
(O2) as additional substrate for catalysis1. Mutations in TH lead to the disease tyrosine hydroxylase deficiency, 
and TH is also a marker for the dopaminergic neurons that degenerate in Parkinson’s disease2. Thus, TH is of 
considerable scientific interest and a focus of intense research.
TH belongs to the BH4-dependent aromatic amino acid hydroxylases (AAAH), a family of enzymes that 
catalyze physiologically and medically important reactions. Phenylalanine hydroxylase (PAH) and tryptophan 
hydroxylase 1 and 2 (TPH1 and TPH2) are the rate-limiting enzymes in the degradation of excess L-phenylalanine 
and the production of serotonin, respectively3. The three enzymes are homotetramers, with each subunit consist-
ing of a regulatory ACT domain with an unstructured N-terminal tail of different length, a catalytic domain 
including the iron coordinated to a 2-His-1-carboxylate facial triad motif4, and an oligomerization domain3,5. For 
PAH, structures of the full-length tetramer from rat were recently solved6,7 but for TH, only truncated forms are 
available. These have provided the crystal structure of the catalytic and oligomerization domains (PDB IDs 1TOH 
and 2XSN)4 and the NMR structure of the regulatory ACT domain (PDB ID 2MDA)8 and enabled construction 
of structural models for full-length TH3,5,8, which await experimental validation.
A complete understanding of the complex structure, catalytic mechanism, and regulatory properties of TH 
and other AAAHs requires protein preparations of high homogeneity. The first studies on isolated TH used 
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native enzyme isolated from neuroendocrine tissues, purified as a partially inhibited catecholamine–enzyme 
complex9,10, and later strategies have provided recombinant human TH in large quantities as a pure, uninhibited 
enzyme with high enzymatic activity11,12. However, structural investigations of full-length TH have so far been 
unsuccessful. TH manifests inherent kinetic and conformational instability, which is partly counteracted by the 
binding of regulatory catecholamines13,14.
Recombinant proteins often aggregate either during expression and purification, or upon storage and handling 
at high concentrations. A common strategy to reduce aggregation is to fuse the target protein to a more stable 
protein, which is removed by specific proteases in the last step of the purification. In this respect, not only the 
yield and purity, but also properties such as solubility, conformation, and toxicity of the protein of interest may be 
dependent on the chosen fusion partner15. Nakashima et al. expressed TH with maltose-binding protein (MBP) as 
an N-terminal fusion partner already in 199116. However, they discovered that Factor Xa, the protease required to 
separate fusion partners in the pMAL system, also cuts within the N-terminus of TH. Higgins et al. circumvented 
this problem by using a tobacco etch virus (TEV) protease-cleavable MBP-TH variant17. However, compared to 
other published data on recombinant TH11,18, they obtained an enzyme with low activity.
Since Nagatsu et al. first isolated TH, it has been known that the addition of Fe2+ stimulates TH activity1. Native 
TH has been reported to contain significant amounts of iron (0.66 mol/mol TH subunit) and zinc (0.13 mol/mol 
TH subunit) when isolated from bovine adrenal medulla10, or up to 1 mol iron/mol TH subunit when isolated 
from rat pheochromocytoma (PC12) cells19. The use of buffers containing 1 mM ethylenediaminetetra-acetic 
acid (EDTA) provided recombinant TH largely as an apoenzyme, with a metal content reported to be as low as 
0.04 mol iron and 0.02 mol zinc per mol of TH11. The requirement of TH for Fe2+ for catalytic activity, associated 
to the formation of the reactive Fe(IV) = O hydroxylating intermediate20, appears absolute, and TH activity is 
inhibited by other divalent metals, such as Zn2+, Co2+ and Ni2+ 11. The absolute requirement for iron also applies 
to the important regulatory function of DA. DA, produced by DOPA decarboxylase from L-DOPA, and the 
other downstream catecholamines noradrenaline and adrenaline act as feedback inhibitors of TH by coordinating 
directly to the iron and inhibiting catalysis. Recently, the importance of the concomitant stabilizing effect of DA 
has also been shown to be crucial for the correct localization of TH in the brain18.
In the current study, we aimed to produce stable, homogeneous preparations of recombinant human TH 
isoform 1 (TH1) for structural investigations. Of the four human TH isoforms, originated by alternative splicing 
(TH1-TH4), TH1, which is very abundant in brain and aligns well with rodent TH, is the one customarily used 
in in vitro investigations21. We present strategies that resulted in two preparations of TH1, expressed from pET-1a 
vectors, with improved stability and homogeneity. These are thus more suitable for both functional and structural 
studies compared to TH1 expressed without a fusion partner22. Interestingly, the most stable preparation was 
a partly inhibited enzyme that contains cobalt in the active site. These purification strategies resulted in TH1 
samples that provided high-quality small-angle X-ray scattering (SAXS) data and allowed the construction of 
structural models for the full-length enzyme.
Results
Cloning, expression, and purification of TH1 with different partners. We tested and compared 
recombinant human TH1 expressed without fusion partner and purified on Heparin Sepharose (TH1(Ctrl); 
Fig. 1a)11 with TH1 expressed as fusion proteins. The original TH1(Ctrl) preparations, with a flexible, unprotected 
N-terminal tail during expression, often show heterogeneity in the N-terminus and variable stability between dif-
ferent purifications. We therefore designed constructs for expressing TH1 fused via a TEV protease site to either 
His6-ZZ – with ZZ being a synthetic IgG-binding domain – or to His6-MBP. These were purified on TALON metal 
affinity resin via their His6-tags and, in the case of His6-MBP-TH1, also on amylose resin. The yield from TALON 
was higher for His6-ZZ-TH1 than for His6-MBP-TH1 so we preferred the former for purifications on TALON 
and the latter for purification on amylose resin (Fig. 1). Cleaved fusion proteins were centrifuged to remove insol-
uble aggregates and subjected to gel filtration to separate tetrameric TH1 from soluble aggregates and cleavage 
products (fusion partner and TEV protease). We observed a markedly higher proportion of soluble aggregates for 
TH1(MBP) than for TH1(ZZ) (Fig. 1b). Edman analysis confirmed that both TH1 proteins have an identical and 
complete N-terminus (Fig. 1a). Although not as good as for TH1(Ctrl), the yield of TH1(MBP) and TH1(ZZ) was 
still sufficiently high (4–6 mg/L culture, when using autoinduction medium).
TH activity and time-dependent inactivation of TH1. In order to determine if the activity of TH1 is 
affected by the used purification strategies, we measured the specific activity of the preparations using a standard 
reaction mixture both with and without 10 μM Fe2+. Addition of Fe2+ is customarily used in TH activity assays to 
ensure that maximal activity is reached11. As expected, the activity was higher upon addition of iron, notably for 
TH1(Ctrl) and TH1(MBP). Under the standard activity assay conditions, with Fe2+ added, TH1(MBP) showed 
the largest activity, followed by TH1(Ctrl) and TH1(ZZ) (Fig. 2a). However, when time-dependent loss of activity 
was measured upon incubation of the enzyme at 37 °C, both TH1(Ctrl) and TH1(MBP) lost >50% of their initial 
activity after 5 h and ≥80% after 24 h. Surprisingly, TH1(ZZ) maintained >50% of its activity up to 24 h (Fig. 2b).
Thermal stability of TH1. The conformation and thermal stability of TH1(ZZ) and TH1(MBP) were inves-
tigated by circular dichroism (CD) spectroscopy. The far-UV spectra (Fig. 3a, inset) showed local minima at 208 
and 222 nm, characteristic of a well-folded helical structure. The estimated α-helical content ranged between 35% 
and 41% and correlated well with reported values for TH1(Ctrl) (Table 1)23. Thermal unfolding experiments pro-
vided the midpoint melting temperature (Tm) after normalization and fitting of the profiles to a two-state model 
(Fig. 3a, Table 1). The results revealed that both TH1(ZZ) and TH1(MBP) were more stable than the control TH1, 
but surprisingly, the Tm of TH1(ZZ) was almost 3 °C higher than that of TH1(MBP) (Table 1).
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Aggregation propensity of TH1(ZZ) and TH1(MBP). As a further characterization of the improved 
recombinant TH1 forms, we applied dynamic light scattering (DLS) to investigate how the hydrodynamic diam-
eter of TH1(ZZ) and TH1(MBP) changed as a function of temperature. The intensity size distribution in DLS 
showed two populations at 5 °C for both TH1 preparations (Fig. 3b, inset), a large population of TH1 with a 
diameter of ∼15 nm, and a smaller one of ∼105 nm. The former value corresponds well to the expected diameter 
of TH in tetrameric structural models3, whereas the population with a larger diameter points to soluble oligo-
meric aggregates. On the other hand, the volume size distribution obtained from the DLS scans at 5 °C revealed 
single populations with an apparent hydrodynamic diameter of 11.9 ± 1.2 nm and 13.2 ± 1.4 nm for TH1(ZZ) 
and TH1(MBP), respectively (Fig. 3b). This result indicates that the highly scattering aggregates detected in the 
size distribution profiles are only present in tiny amounts. DLS thermal scans showed a lower aggregation pro-
pensity for TH1(ZZ) than for TH1(MBP) (Fig. 3c), supporting the results from gel filtration chromatography of 
Figure 1. The three TH1 preparations. (a) Simplified illustration of vector constructs used in this study, 
leading to the following TH1 forms: TH1(ZZ) purified on TALON resin as His6-ZZ-TH1 and cleaved by TEV 
protease (green), TH1(MBP) purified on amylose resin as His6-MBP-TH1 and cleaved by TEV protease (red) 
and TH1(Ctrl) purified on Heparin Sepharose (blue). Open reading frames for ampicillin (Amp) or kanamycin 
(Kan) resistance genes and TH1 fusion proteins are shown as arrows, and cleavage sites for proteases are 
indicated. Amino acids of the N-termini revealed by Edman analysis are highlighted in orange. (b) Analytical 
gel filtration chromatogram of TH1(ZZ) (green) and TH1(MBP) (red) on a Superdex 200 Increase 10/300 
column. The elution profile illustrates the separation of aggregates, tetrameric TH1 and the other cleavage 
products (fusion partner and TEV protease). Insets: SDS-PAGE of 2 μg purified protein. Lane 1: prestained 
protein ladder; lane 2: fusion protein; lane 3: cut fusion protein; lane 4: purified TH1.
www.nature.com/scientificreports/
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cleaved fusion proteins (Fig. 1b) and the higher thermal stability for TH1(ZZ) measured by thermal scanning CD 
(Fig. 3a).
Metal content in TH1 preparations. As a part of the characterization of the physicochemical properties 
of TH1(ZZ) and TH1(MBP), we investigated their metal content. Both TH1 forms are expressed from similar 
pET-1a vectors, with the only difference being the fusion partner and the type of affinity resin used during puri-
fication, i.e. TALON for the purification of TH1(ZZ) and amylose resin for the purification of TH1(MBP). TH1 
shows an absolute requirement for iron for catalysis, while other metals have been reported to bind and inhibit 
TH1, leading to an inability to catalyze L-DOPA formation from L-Tyr11,24. As measured by inductively coupled 
plasma mass spectrometry (ICP-MS), TH1(ZZ) contained almost no iron (0.06 ± 0.07 mol/mol TH1 subunit) 
compared to TH1(MBP) (0.25 ± 0.18 mol/mol TH1 subunit). The specific activity of TH1(ZZ) was lowest, regard-
less of added Fe2+ (Fig. 2a), and resembles the activity of TH1(Ctrl) without added Fe2+, which is largely purified 
as an apoenzyme. We thus hypothesized that the active site might be occupied by another metal than iron, most 
probably cobalt, the metal that coordinates to the His tag on the TALON resin. We performed further metal 
quantifications and did, indeed, observe high amounts of cobalt in TH1(ZZ) (0.70 ± 0.25 mol/mol TH1 subunit), 
while no cobalt was detected in TH1(MBP).
The origin of the higher stability of TH1(ZZ). In order to investigate whether the unique high stabil-
ity of TH1(ZZ) (high Tm and low aggregation propensity) is intrinsically associated to the cobalt in the active 
site, or to its fusion with the ZZ partner during expression and initial purification, we purified His6-ZZ-TH1 on 
Heparin Sepharose, following the purification protocol for TH1(Ctrl). This TH1, obtained after cleavage with 
TEV protease, had thus not been in contact with the cobalt-containing TALON resin during purification and 
was – as TH1(MBP) – found to be devoid of cobalt. CD-monitored thermal denaturation provided a Tm-value of 
50.1 ± 0.6 °C for TH1(ZZ)Heparin Sepharose (Fig. 4a), 3 °C higher than the Tm for TH1(Ctrl) but ∼5 °C lower than for 
TH1(ZZ)TALON (Table 1). This shows that the substantial increase in stability of TH1(ZZ) is conferred not by the 
protein construct itself, but by the purification on TALON metal affinity resin, which most likely releases cobalt 
to the enzyme preparation.
Figure 2. The activity of the TH1 preparations. (a) Specific TH1 activity of TH1(Ctrl) (blue), TH1(ZZ) 
(green) and TH1(MBP) (red), with (closed bars) and without (hatched bars) addition of 10 μM Fe2+ in the assay. 
The data represent the mean ± combined SD of at least four independent measurements each performed in 
triplicates. (b) Remaining TH1 activity (% of initial activity) as a function of pre-incubation time. The activity 
of TH1(Ctrl) (blue), TH1(ZZ) (green), and TH1(MBP) (red) was measured with 50 μM L-Tyr and 200 μM BH4 
after 5 min, 1 h, 5 h and 24 h pre-incubation at 37 °C, pH 7.0. The data represent the mean ± combined SD of 
two independent measurements where each data set was performed in triplicates and normalized to the initial 
activity (5 min pre-incubation).
www.nature.com/scientificreports/
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Figure 3. Stability of the TH1 forms. (a) CD-monitored (at 222 nm) thermal denaturation of TH1(ZZ) 
(green) and TH1(MBP) (red). TH1 (4 μM subunit) was in 10 mM Na-HEPES pH 7.0, 100 mM NaCl. The 
fraction unfolded TH1 data are the mean of six replicates. Inset: Far-UV CD spectra of 4 μM TH1(ZZ) (green) 
and TH1(MBP) (red) at 5 °C in 10 mM Na-HEPES pH 7.0, 100 mM NaCl. The data represent the mean of six 
replicates. Tm values and estimated α-helical content are summarized in Table 1. (b) DLS size distribution of 
TH1. Volume size distribution of TH1(ZZ) and TH1(MBP) at 5 °C in 10 mM Na-HEPES pH 7.0, 100 mM NaCl. 
Inset: Intensity size distribution at 5 °C. The DLS data represent the mean of three replicates. (c) DLS thermal 
stability of TH1(ZZ) and TH1(MBP). DLS thermal scans of TH1(ZZ) (green) and TH1(MBP) (red), both with 
18 μM subunit in 10 mM Na-HEPES pH 7.0, 100 mM NaCl.
Circular dichroism
α-helix content (%) Tm (°C)
TH1(Ctrl) 42 ± 223 4723
TH1(ZZ)TALON 39.8 ± 9.1 55.1 ± 0.6
TH1(MBP) 34.9 ± 4.8 52.5 ± 0.3
TH1(ZZ)Heparin Sepharose 40.7 ± 13.8 50.5 ± 0.3
Table 1.  Alpha-helical content and thermal stability of the different TH1 constructs. In all cases, n = 6.
www.nature.com/scientificreports/
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Dopamine binding. An important regulatory mechanism for TH is the binding of DA to the iron in the 
active site that both inhibits and stabilizes TH9,13,14. Although TH1(ZZ) has desirable properties with regards 
to stability, TH1 used for functional studies must be properly regulated. Therefore, we tested whether our 
improved TH1 proteins can bind and be stabilized by DA using CD-monitored thermal denaturation. The Tm 
for TH1(MBP), as also recently shown by Korner et al. using differential scanning fluorimetry18, increased by 
approximately 3 °C upon the addition of 8 μM DA, i.e. a saturating concentration based on the IC50 of 1.9 μM for 
DA25. The Tm of DA-bound TH1(MBP) is similar to that of purified Co-bound TH1(ZZ), which was only slightly 
stabilized by DA (≤1 °C) under similar conditions (Fig. 4b).
The SAXS solution structure of full-length TH1. Based on the good conformational properties of 
TH1(MBP) and TH1(ZZ), we expected that these enzyme forms would be amenable to structural characteri-
zation and proceeded to perform synchrotron SAXS measurements. Due to its higher stability, we argued that 
TH1(ZZ) was the most promising candidate for further structural studies. Indeed, several preparations of this 
sample were tested that presented little aggregation or radiation damage. While both TH1(MBP) and TH1(ZZ) 
provided similar scattering curves, notably TH1(MBP) presented some aggregation (see Supplementary Fig. S1). 
SAXS data collection and parameters obtained for TH1(ZZ) are shown in Table 2. These data were used for mod-
elling of the full-length solution structure of TH1. The MW based on forward scattering confirmed the presence 
of a tetramer, with an experimental radius of gyration Rg = 4.74 ± 0.33 nm and a maximum interatomic distance 
Dmax = 20 nm, indicating an elongated shape. This conformation is supported by both the distance distribution 
function (Fig. 5a) and ab initio modelling. The chain-like ab initio shape, built using the expected P222 symmetry, 
shows approximate dimensions of 17 × 9 × 9 nm, with a dense equatorial core, corresponding to the catalytic and 
oligomerization domains, and two smaller densities on each side of the core, extending out into the solvent (see 
Supplementary Fig. S2).
To obtain a more detailed structure of the complex we employed a multiscale modelling protocol using 
(1) components determined previously from crystallography and NMR, (2) homology modelling, and (3) pro-
tein structure folding through molecular simulations. These components were combined through SAXS-based 
simulated annealing protocols (see Methods). The 70-amino-acid N-terminal sequence was divided into three 
segments: (1) residues 1–35, (2) residues 36–44, and (3) residues 45–70. Residues 1–35 were modelled ab initio 
Figure 4. Effect of purification on metal affinity resin on TH1 stability. CD-monitored (at 222 nm) thermal 
denaturation of TH1 (4 μM subunit) in 10 mM Na-HEPES pH 7.0, 100 mM NaCl. (a) TH1 purified as a His6-ZZ 
fusion, either on TALON (TH1(ZZ)TALON, green) or on Heparin Sepharose (TH1(ZZ)Heparin Sepharose, orange). 
The denaturation profile for control TH1 purified without fusion partner is also shown (TH1(Ctrl), blue). The 
data represent the mean of six replicates. (b) TH1(ZZ) purified on TALON and TH1(MBP), both in the absence 
(solid line) and presence (dotted line) of twice the stoichiometric amounts of DA (8 μM). The data represent the 
mean of four replicates.
www.nature.com/scientificreports/
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during the simulated annealing protocol of the full complex using BUNCH26. Residues 36–44 contain a motif that 
aligns well with the corresponding residues in PAH (see Supplementary Fig. S3). Since these residues are resolved 
in the PAH crystal structure27, we used homology modelling to obtain coordinates for this segment in TH. 
Residues 45–70 contain an Ala-rich segment, which we suspected could obtain a folded structure due to the abil-
ity of poly-Ala peptides to form α-helices. This Ala-rich N-terminal segment (Ala45-Ala70) was issued to exten-
sive replica exchange molecular dynamics (REMD) simulations to explore a likely three-dimensional structure 
(see Methods). Cluster analysis based on pairwise structural deviations grouped the 10,000 conformations into 
five distinct clusters. 9,572 of the 10,000 conformations were grouped into one major cluster (cluster 1) dominated 
by members with high α-helix propensity and a compact structure with a mean Rg of 0.88 nm (SD = 0.06 nm). 
A majority of the cluster members showed an α-helix at residues Lys47-Ala56 (see Supplementary Fig. S4). In 
contrast, the remaining 428 conformations (clusters 2–5) showed a more elongated configuration with a mean Rg 
of 1.44 nm (SD = 0.21 nm), also showing several members with an α-helix in the same region as for cluster 1. The 
cluster representative from cluster 1 contains an α-helix from Lys47 to Ala58 and a random coil from Val60 to 
Ala70. This configuration is in agreement with secondary structure predictions using PSIPRED28, which suggest 
Arg46-Ala59 to be an α-helix. This fragment of the N-terminal segment was connected to the ACT domains for 
SAXS-based rigid body modelling.
SAXS-based rigid body modelling was performed with BUNCH using P222 symmetry with the subunit chain 
built up from residues 1–35 (unstructured); residues 36–44 covering over the active site of the catalytic domains 
modelled through homology with equivalent residues from PAH6; residues 45–70 folded through REMD sim-
ulations described above; ACT domains obtained from the NMR structure8; the catalytic and oligomerization 
domains derived from crystallography4. The ACT, catalytic domains, and tetramerization domains were con-
nected with flexible linkers allowing these domains to move relative to each other during simulated annealing. 
The simulations yielded a model with an overall very good fit to the raw SAXS data with χ2 of 1.55 (Fig. 5b). The 
model shows a tetramer, in which the catalytic domains orient in a similar way as in the crystal structure (PDB 
ID 2XSN), but with a tilt between the two dimers, making an out-of-plane tetramer (see Supplementary Fig. S5 
for comparison with in-plane configuration in the crystal structure). The ACT domains are oriented above the 
tetramerization helix bundle, with the N-terminus of each ACT domain pointing towards the corresponding 
catalytic domain active site.
The importance of the disordered N-terminal tails of the model on the fit to the SAXS data is apparent; remov-
ing residues Met1-Ile35 provides a worse fit to the SAXS curves with a χ2 of 2.0. This supports the notion that the 
flexible N-terminal tails extend into bulk solvent from the protein core. Furthermore, modelling of TH based on 
SAXS analyses
Data-collection parameters
 Instrument P12 beam line (PETRA-III, DESY)
 Wavelength (nm) 0.124
 s range (nm−1) 0.02–4.8
 Exposure time (s) 0.045
 Concentration range (mg/mL) 0.5–2.0
 Temperature (°C) 20
Structural parameters
 I(0) (relative) [from p(r)]* 63,360.0
 Rg (nm) [from p(r)] 4.93
 I(0) (relative) [from Guinier]* 62,494.4 ± 124.65
 Rg (nm) [from Guinier] 4.74 ± 0.33
 Dmax (nm) 20.0
 Porod volume estimate (nm3) 519.79
 Dry volume of a monomer calculated from sequence (nm3) 67.56
Molecular mass determination
 Molecular mass Mr (kDa) [from I(0) using p(r)] 287.8
 Molecular mass Mr (kDa) [from I(0) using Guinier] 283.8
 Calculated monomeric Mr from sequence 55.8
Software employed
 Primary data reduction PRIMUS
 Data processing PRIMUS
 Ab initio analysis GASBOR
 Validation and averaging PRIMUS
 Rigid-body modelling BUNCH
 Computation of model intensities CRYSOL
 Three-dimensional graphics representation PyMOL
Table 2.  SAXS data-collection and scattering-derived parameters. *After normalization to a concentration 
of 1 mg/mL.
www.nature.com/scientificreports/
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the tetrameric organization of the catalytic and tetramerization domains (as seen in the crystal structures, PDB ID 
2XSN and 1TOH) combined with the NMR structures of the dimerized ACT domains (PDB ID 2MDA) without 
rigid body movements of the catalytic domains and without the N-terminal residues (1–35) gives a suboptimal 
fit with a χ2 of 10.5 (Fig. 6a). Including the N-terminal residues improves the agreement with the SAXS data (χ2 
of 5.8; Fig. 6b), but the fit is much worse than for the model with the catalytic domains adjusted (out-of-plane 
as shown in Fig. 5). Fitting was also inadequate when the dimerized ACT domains were substituted by sepa-
rated ACT domains, as encountered in the recently solved crystal structure of inactivated PAH (PDB ID 5DEN)6 
(Fig. 6c). Also in this case a large increase in χ2 is observed (to 7.83), supporting our SAXS-derived model.
SAXS measurements were also carried out with TH1(MBP) in order to analyze the structural effects of DA 
binding. The results in the absence and presence of DA indicate that DA binding does not induce large confor-
mational changes in TH1 (see Supplementary Fig. S1), in agreement with H/D exchange studies showing that DA 
binding mainly affects the N-terminus and some residues close to the active site29.
Figure 5. Small-angle X-ray scattering of TH1(ZZ). (a) Distance distribution function. (b) Raw X-ray 
scattering data (blue dots) and the fit of the model (red line). (c) Model of TH obtained by hybrid modelling 
shown in three orientations. Coloring depicts the various structural elements and domains of TH1: N-terminal 
tails (Met1-Asp44); Ala-rich region of N-terminal region (Ala45-Ala70); ACT domain (Val71-Arg156); catalytic 
domains (Ser157-Asp470); and tetramerization helices (Ser471-Gly497); numbering corresponds to human 
TH1. (d) Model in surface representation with colors representing the four subunits in the complex.
www.nature.com/scientificreports/
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Discussion
Improved TH1 purifications. The preparations of TH1 characterized in this work show differences in TH1 
activity and thermal stability depending on the choice of fusion partner and/or type of affinity chromatography 
resin. Compared to the control TH1, which has no fusion partner and is purified on Heparin Sepharose, our new 
preparations have higher thermal stability and are less prone to aggregation, most likely due to a more homo-
geneous N-terminal region. The N-terminal tail of TH1 is very flexible, and residues 1-43 were shown to have a 
Figure 6. Evaluation of models. The models were evaluated using the tetrameric organization of catalytic 
domains (CD) as seen in the crystal structures (shown for human TH, PDB ID 2XSN) combined with 
dimerized ACT domains without (a) and with (b) N-terminal residues (1–35). These models without adjusting 
the positions of the CD provide χ2 values of 10.5 and 5.8, respectively. The model with ACT domains separated 
(c) shows a clear difference in the SAXS profile.
www.nature.com/scientificreports/
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disordered conformation by solution NMR8, CD, and molecular dynamics simulations30, rendering it vulnerable 
to proteolytic degradation. To overcome this problem, we designed several fusion proteins of TH1, all containing 
the fusion partner at the N-terminal end of TH1. In addition to facilitating purification, the fusion partner MBP 
can enhance solubility and promote folding by acting as a general molecular chaperone. The latter is thought 
to be due to MBP binding the protein of interest via its exposed hydrophobic residues and by MBP recruiting 
chaperones, like GroEL, present in the E. coli host cell31. Differently to the case with fusion proteins of MBP with 
a Factor Xa cleavage site16, we obtained full-length TH1(MBP) preparations with an intact N-terminus and a high 
activity from the His6-MBP-TH1 fusion protein cleaved by TEV protease. This protease is also used with TH1 
from pET-ZZ-1a that produces TH1 with His6-ZZ, a smaller fusion tag of 17 kDa (Fig. 1a). The ZZ fusion may 
pose less of a metabolic burden on the host cell than the larger fusion partner MBP, and the ZZ domain has also 
been used to solubilize proteins that tend to aggregate during expression32, probably explaining the higher yield 
of TH1 obtained from His6-ZZ-TH1 than from His6-MBP-TH1 purified on TALON.
Cobalt-bound TH1(ZZ) is remarkably stable. Although it is generally not recommended to purify 
metal-containing proteins on metal affinity resins, we have previously successfully purified several bacterial forms 
of PAH as His6-tagged fusion proteins on TALON columns33,34. One of these was, indeed, purified almost solely 
as an apoenzyme, but it displayed very high activity upon reconstitution with iron33. This was, however, not 
the case for TH1. The increase in enzymatic activity of TH1(ZZ) purified on TALON upon addition of iron in 
the assay was not significant and much lower than that observed for both TH1(Ctrl) and TH1(MBP) (Fig. 2a). 
However, the activity and conformation of TH1(ZZ) show increased thermostability. As measured by ICP-MS, 
TH1(ZZ) contains cobalt in substantial amounts, and we assumed that the cobalt – originating from the purifi-
cation resin – is the inhibiting and stabilizing element24. The enzyme purified from the same His6-ZZ-TH1 con-
struct, but on Heparin Sepharose instead of TALON, did not exhibit this increase in stability (Fig. 4a). Indeed, it 
has also been shown for other metalloenzymes that their cobalt-bound state is more stable than the iron-bound 
form35,36. Although we acknowledge the fact that a cobalt-containing TH1(ZZ) is not suited for specific functional 
and regulatory studies, its improved stability makes it a promising candidate protein for structural studies of 
full-length TH1 — a long awaited milestone in the study of this enzyme. For functional studies, we may prefer to 
use TH1(MBP), an enzyme that presents high specific activity, a homogeneous N-terminus, and stabilization by 
the natural end-product inhibitor DA.
The SAXS-derived structure of full-length TH1. We obtained the first experimental three-dimensional 
structure of full-length tetrameric TH1 by SAXS using TH1(ZZ) preparations. The SAXS structure resembles that 
of structural models of TH1 prepared recently based on combinations of crystal and NMR structures of the dif-
ferent domains3,8. Nevertheless, whereas the crystal structure of tetrameric catalytic and oligomerization domains 
presents all four catalytic domains in-plane4, the SAXS data fit best to a model in which the catalytic domains are 
out-of-plane (see Supplementary Fig. S5). Structural differences between solution and crystalline states have been 
reported for several proteins6,7,37. For instance, the recent solution structure of PAH7 revealed a V-shaped asym-
metry in the tetramer that adds to the asymmetry in the dispositions of the domains that is already encountered 
in the crystal structures of tetrameric PAH6,38 and that has been interpreted to be related to the flexible nature of 
an allosteric tetramer that shows positive cooperativity for its substrate7. Despite devoid of the positive cooper-
ativity for its substrate, characteristic of PAH3,5, allosteric effects of the natural BH4 cofactor on TH activity have 
been described, including both positive cooperativity that is counteracted by DA neurotoxin39, as well as negative 
cooperativity40, which might also been related to allosteric and/or regulatory conformational changes in TH.
Even though TH and PAH have a very similar geometry and size with respect to the core ACT, catalytic and 
regulatory domains, the dimensions of TH1 and PAH are rather different. TH1 adopts a more elongated shape 
(Rg = 4.74 ± 0.33 nm, Dmax = 20 nm) than full-length PAH (Rg = 4.05 nm, Dmax = 11.7 nm)6, which is only 10% 
smaller in MW than TH1, revealing the large impact of the unstructured N-terminal region on the shape of TH1 
(Fig. 5). Our SAXS-based structure contributes to the structural and functional understanding of TH and comple-
ments previous models by including the modelled N-terminal region (residues 1–70; see Supplementary Fig. S3). 
Previous conformational studies using the isolated 1-43 residues from the N-terminal tail have shown that it 
presents intrinsic disorder, but that it has a tendency to adopt α-helical secondary structure, e.g. upon interaction 
with membranes30. This mobile and unstructured tail is the part of TH1 that contains the phosphorylation sites 
Thr8, Ser19, Ser31, and Ser40 that regulate activity and interactions with partners21,41. Interestingly, the modelled 
structure maintains Ser40 close to the entrance of the active site, at a suitable distance to interact with DA and 
other catecholamines, and to contribute to the high-affinity binding of these feedback inhibitors, an interaction 
that is released upon Ser40 phosphorylation by cAMP dependent protein kinase42. Furthermore, the SAXS model 
reveals an arrangement of the N-terminal tail pointing out from the globular domains, which is in agreement 
with the site of binding of the 14-3-3γ protein in the phosphoSer19-TH:14-3-3γ complex, as observed by EM43. 
Actually, the Ala-rich motif also appears as a well-located docking interface for partner protein interactions that 
may modulate the localization, function and stability of TH. Recently, affinity capture-MS data on the human 
interactome has revealed a large number of protein-protein interactions of TH, as expected for a tightly regulated 
enzyme44 and the present structural model of the N-terminal region of TH certainly shows features compatible 
with a multi-partner protein. Finally, the SAXS data and derived model validate a dimeric disposition of the ACT 
domains (Fig. 6c). A recent study has also shown that the ACT domains of TPH1 form a structural homodimer, 
indicating that a dimeric arrangement of adjacent domains may also be a feature in the full-length TPH45. This is 
similar to the arrangement found for PAH only when it is activated by its substrate L-Phe. In the inactivated PAH 
the ACT domains do not interact with one another and transition to dimeric state is associated to activation by 
L-Phe6,7. Neither TH nor the TPHs are activated by their substrates and thus such a monomer-dimer exchange 
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may not take place in these hydroxylases. Importantly, a dimerized configuration of the regulatory domains seems 
to provide increased stability45.
In conclusion, we present the preparation of highly pure, stable forms of full-length TH1. TH1(MBP) shows 
a high activity level, is activated by Fe2+, and is stabilized by regulatory DA, but it is less stable than TH1(ZZ). On 
the other hand, TH1(ZZ) is stabilized by cobalt, which largely inhibits its activity but protects the enzyme from 
denaturation and aggregation. This preparation allowed the characterization of the structural organization of 
full-length TH by SAXS, which has until now been hindered, most likely by the low stability and large heteroge-
neity in earlier TH preparations. The SAXS-derived structure presents full-length TH with dimeric ACT domains 
and an elongated conformation due to a large influence of the unstructured N-terminal region compared with 
PAH. This long N-terminal region (residues 1–70) is important for regulation of TH by phosphorylation and for 
interaction with partners.
Methods
Cloning strategies. The pET-TH expression vector, generated by Le Bourdellès et al.22 by cloning the TH1 
cDNA into pET-3a, was used as a basis for constructing other expression vectors. Insertion of TH1 into both pET-
ZZ-1a and pET-MBP-1a was performed by PCR using the primers 5′- GCTTCCATGGGACCCACCCCCGA-3′ 
and 5′-GCTTGGTACCCAGTGCAGGACCA-3′ and the restriction enzymes NcoI and Acc65I, resulting in an 
extra glycine residue in position 2 and the residues glycine and alanine in front of the starting methionine after 
removal of the fusion partner. Correct sequences were verified by sequencing.
Expression and purification of recombinant TH1 proteins. TH1 protein variants were overexpressed 
in E. coli BL21-CodonPlus(DE3)RIL. Briefly, cells were grown at 28 °C and 200 rpm in LB medium with 1 mM iso-
propyl β-D-thiogalactoside added for induction at an OD600nm of 0.6 for 6 h, or in autoinduction medium for 24 h, 
supplemented with 0.2–1 mM Fe2+ (as ferrous ammonium sulfate) and the appropriate antibiotic (Fig. 1a). Fusion 
proteins were purified at 4 °C using the appropriate affinity chromatography resin (Fig. 1a). The equilibration 
and wash buffers used were 20 mM Na-HEPES pH 7.0, 200 mM NaCl for amylose resin, 20 mM Na-phosphate 
pH 7.0, 300 mM NaCl, 15 mM imidazole for TALON® Superflow™ Metal Affinity Resin, and 20 mM Tris-HCl 
pH 7.5, 1 mM EDTA, 1 mM dithiothreitol (DTT), 5% sucrose (w/v) with Heparin Sepharose. Bacterial cells were 
disrupted by sonication (3 × 45 s pulses at 20% power) or French press in buffers with 1 mM phenylmethanesul-
fonyl fluoride, 10 mM benzamidine and cOmplete™ EDTA-free Protease Inhibitor Cocktail. The clarified extract 
was applied to the resin at 1–2 mL/min. After washing, bound proteins were eluted using wash buffers with either 
15 mM maltose (amylose resin), 135–250 mM imidazole (TALON Superflow resin), or 0.5 M NaCl (Heparin 
Sepharose). Imidazole was removed from eluted fractions by buffer exchange.
The fusion protein, incubated with TEV protease46 at 4 °C for 1–3 h, was loaded into a HiLoadTM SuperdexTM 
200 prep grade column (1.6 cm × 60 cm) to purify soluble tetrameric TH1 or into a Superdex 200 Increase GL 
column (1.0 cm × 30 cm) for analytical purposes. Protein concentration was measured at 280 nm, using the theo-
retical molar extinction coefficient of 40,715 M−1 cm−1.
N-terminal sequencing. N-terminal sequencing was performed by the Proteome Factory AG (Berlin, 
Germany), using Edman analysis. Samples were prepared according to standard protocols for semidry blotting on 
a polyvinylidene difluoride membrane. TH1(Ctrl), TH1(ZZ), and TH1(MBP) samples (Fig. 1a) were sequenced 
with 5 steps to determine a 5-amino-acid sequence.
TH activity assay. TH activity was measured as described11 with minor modifications. Briefly, TH1 (0.1 mg/mL, 
1.8 μM subunit) was pre-incubated with 1% BSA (w/v) in 20 mM Na-HEPES pH 7.0, 200 mM NaCl on ice. 5 μL 
aliquots were incubated for 1 min in a standard reaction mixture containing 50 μM L-Tyr, 0.1 mg/mL catalase, 
and 10 μM Fe2+ in 40 mM Na-HEPES pH 7.0, or in this mix without Fe2+. The reaction was started by adding 
200 μM BH4 in 2 mM DTT, stopped after 5 min with 2% acetic acid in ethanol (v/v), frozen at -20 °C for at least 
30 min, and centrifuged for 15 min at 4 °C and 18,000 × g. The amount of L-DOPA was measured in the superna-
tants by high-performance liquid chromatography analysis with fluorescence detection, as described47. For the 
time-dependent TH activity assay, the pre-incubation was at 37 °C and included 1 μM Fe2+, and aliquots were 
taken out after 5 min, 1 h, 5 h, and 24 h and measured in the standard reaction mix.
Circular dichroism spectroscopy. CD measurements were performed on a Jasco J-810 spectropolarimeter 
equipped with a CDF-426S Peltier element for temperature control. Far-UV CD spectra between 180–260 nm 
were acquired at 5 °C by using 0.2 nm data pitch, 2 nm band width, 20 nm/min scan speed, and accumulation 
of 4 spectra. CD spectra of TH1 (4 μM subunit) in a 1 mm quartz cell were acquired in 10 mM Na-HEPES pH 
7.0, 100 mM NaCl. Baseline buffer spectra were subtracted. Thermal denaturation of TH1 (4 μM subunit) was 
recorded from 5 to 80 °C at 222 nm with a scan rate of 2 °C/min and 0.2 °C data pitch. DA binding to TH1(ZZ) 
and TH1(MBP) was tested by adding twice the stoichiometric amount of DA. All thermal scans were normalized, 
fitted to a two-state unfolding model48, and further converted to fraction of unfolded protein as described49. 
CDNN50 was used to estimate secondary structure content.
Dynamic light scattering. DLS was performed on a Malvern Zetasizer Nano ZS instrument, using a HeNe 
laser at 633 nm and a fixed scattering angle of 173° (back scatter). Temperature scans were recorded from 5 to 
80 °C, with a temperature interval of 5 °C. TH1 preparations were diluted to 1 mg/mL (18 μM subunit) in 10 mM 
Na-HEPES pH 7.0, 100 mM NaCl. Data analysis was performed on intensity and volume size distribution curves 
and the Z-average size using the Malvern DTS software.
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Metal measurements. Iron and cobalt content of the TH1 preparations was measured by ICP-MS with 
a microwave digestion method. Briefly, TH1 (3 mg/mL, 54 μM subunit) was mixed with ultrapure nitric acid 
(HNO3, 60%) and hydrogen peroxide (H2O2, 30%) in a 5:5:2 v/v/v ratio. Using the Milestone 1200 MEGA 
(Sorisole, Italy), complete TH1 digestion was achieved by a six-stage program and a maximum microwave power 
of 600 W. 20 mM Na-HEPES pH 7.0, 200 mM NaCl and SeronormTM Trace Elements Serum L-1 (SERO) prepared 
in the same way were used as blank and quality control of the digestion method, respectively. The digested sam-
ples (n = 3 for each TH1 form) were transferred to metal-free tubes and quantitatively further diluted by a factor 
of 32.6 with Milli-Q water. Sample introduction into the ICP-MS was performed by the SC-FAST (Elemental 
Scientific) fully automated sample introduction system, in combination with an online internal standard addi-
tion of 1 μg/L indium solution to monitor and correct for instrumental fluctuations. Calibration standard solu-
tions were prepared from certified single-element standard solutions (Spectrapure Standards AS). Analysis was 
done with the Thermo Finnigan Element 2 high-resolution magnetic sector field ICP-MS. The ICP-MS measur-
ing accuracy and calibration curves were monitored by the standard reference material SPS-SW2 (Spectrapure 
Standards AS).
SAXS measurements. SAXS measurements were carried out on the EMBL P12 synchrotron BioSAXS 
beamline51 at PETRA III/DESY, Hamburg, Germany on TH1(ZZ) and TH1(MBP) in 20 mM Na-HEPES pH 7.0, 
200 mM NaCl (0.5–2.0 mg/mL, 9–36 μM subunit). DA in stoichiometric amounts compared to an enzyme subunit 
was added, when indicated. Data were collected at 20 °C using an X-ray wavelength of 0.124 nm and an exposure 
time of 45 ms/frame. 20 consecutive frames were collected for each sample; the sample was flowing through the 
capillary during the measurement. Frames were controlled for radiation damage and averaged. The data were 
recorded using a PILATUS 2M detector (Dectris, Baden, Switzerland) at a sample-detector distance of 3.0 m, 
covering a momentum transfer range, s (4πsinθ/λ) of 0.02–4.8 nm−1, where 2θ is the scattering angle and λ the 
wavelength and s is in units of nm−1.
Data processing and analysis were carried out using the ATSAS package52. Solvent scattering was identically 
measured from the corresponding buffer before and after each sample, and the average background scattering was 
subtracted with PRIMUS53. Rg was determined using Guinier analysis. The maximum particle dimension Dmax 
and the distance distribution function p(r) were calculated using GNOM54. Molecular weights were estimated 
based on forward scattering I(0) from the sample, compared to standard samples of either glucose isomerase or 
BSA.
Structural modelling. To obtain unbiased shape information for full-length TH1, chain-like models were 
built ab initio using GASBOR55. P222 symmetry, as seen in crystal structures of tetrameric species of truncated 
TH and homologues, was used during modelling.
BUNCH was used for SAXS-based rigid body modelling of TH1, using existing crystal and NMR structures as 
rigid body subunits interconnected by flexible loops. We divided the TH1 subunit chain into 3 rigid bodies inter-
connected by flexible loops: (1) the tetramerization helix (coordinates from PDB ID 1TOH4); (2) catalytic domain 
(coordinates from PDB ID 1TOH); (3) ACT domain (atomic coordinates obtained from PDB ID 2MDA8). To 
maintain known interfaces (from the crystal and NMR structures) between domains in the simulated annealing 
protocol we employed distance restraints between (1) two adjacent ACT domains, (2) two adjacent catalytic 
domains, and (3) the tetramerization bundle. CRYSOL56 was subsequently used to calculate the final fit to the 
experimental SAXS data. P222 symmetry and default values for the simulated annealing protocols in BUNCH 
were used, with 100 temperature steps and a maximum of 24,850 iterations at each temperature.
The Ala-rich N-terminal segment Ala45-Ala70 upstream from the ACT domain in TH was issued to extensive 
replica exchange molecular dynamics simulations57 to obtain a representative three-dimensional structure of this 
fragment. A linear all-atom model of the fragment was generated using AmberTools, employing the Amber99SB 
force field58 and implicit solvent model using generalized born59. The replica exchange simulations were run 
over 20 temperatures spanning from 270 to 509 K. Each replica was heated to its respective starting temperature 
during 200 ps. The replica exchange simulations consisted of 10,000 exchanges, each of 4 ps (2 × 107 steps for 
each replica). The simulations were carried out using multisander in the Amber package. The resulting con-
formations at 300 K were extracted and clustered using cpptraj60. The representative structures from the most 
frequently populated cluster were extracted and included adjacent to the ACT domains in the model prior to 
the SAXS-based rigid body simulation. Independent of the replica exchange simulation, PSIPRED was used to 
predict the secondary structure elements in this fragment. The N-terminal residues Gly36-Asp44 of TH1 align 
well with the equivalent residues of PAH (see Supplementary Fig. S3), with high sequence identity, including the 
motif [SXIED]. Based on this alignment, the residues Gly36-Ala45 were modelled in TH1 corresponding to the 
PAH structure (PDB ID 5DEN)6.
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